Analysts expect that Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) will post $1.79 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Dicerna Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $1.70 million and the highest estimate coming in at $1.92 million. Dicerna Pharmaceuticals posted sales of $250,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 616%. The business is scheduled to issue its next earnings report on Thursday, August 9th.
On average, analysts expect that Dicerna Pharmaceuticals will report full-year sales of $5.91 million for the current financial year, with estimates ranging from $2.00 million to $7.97 million. For the next financial year, analysts forecast that the company will report sales of $12.17 million per share, with estimates ranging from $3.10 million to $26.67 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Dicerna Pharmaceuticals.
Get Dicerna Pharmaceuticals alerts:
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.57. The company had revenue of $1.55 million during the quarter, compared to the consensus estimate of $1.75 million. Dicerna Pharmaceuticals had a negative net margin of 1,665.11% and a negative return on equity of 123.72%.
Several equities research analysts have recently commented on DRNA shares. BidaskClub downgraded shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Cowen reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, April 24th. B. Riley started coverage on shares of Dicerna Pharmaceuticals in a research note on Wednesday, March 28th. They set a “neutral” rating and a $10.00 price objective for the company. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, April 12th. Finally, Chardan Capital started coverage on shares of Dicerna Pharmaceuticals in a research note on Friday, March 9th. They set a “neutral” rating for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Dicerna Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $12.88.
In related news, insider James B. Weissman sold 10,000 shares of the firm’s stock in a transaction on Wednesday, May 9th. The shares were sold at an average price of $15.00, for a total transaction of $150,000.00. Following the completion of the transaction, the insider now owns 19,800 shares of the company’s stock, valued at $297,000. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider James B. Weissman sold 8,965 shares of the firm’s stock in a transaction on Friday, April 20th. The stock was sold at an average price of $13.00, for a total transaction of $116,545.00. Following the transaction, the insider now directly owns 9,800 shares of the company’s stock, valued at approximately $127,400. The disclosure for this sale can be found here. Insiders have sold 20,000 shares of company stock valued at $280,000 over the last quarter. Insiders own 19.85% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC purchased a new position in shares of Dicerna Pharmaceuticals during the first quarter worth $102,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Dicerna Pharmaceuticals during the first quarter worth $113,000. Caxton Corp purchased a new position in shares of Dicerna Pharmaceuticals during the first quarter worth $125,000. Jane Street Group LLC purchased a new position in shares of Dicerna Pharmaceuticals during the first quarter worth $136,000. Finally, Verition Fund Management LLC purchased a new position in shares of Dicerna Pharmaceuticals during the first quarter worth $141,000. 77.28% of the stock is owned by hedge funds and other institutional investors.
DRNA traded down $0.08 during trading on Friday, hitting $12.50. The stock had a trading volume of 667,152 shares, compared to its average volume of 510,417. The company has a market cap of $688.27 million, a price-to-earnings ratio of -3.42 and a beta of 2.34. Dicerna Pharmaceuticals has a twelve month low of $2.69 and a twelve month high of $15.80.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.
Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com